Laser Interstitial Tumor Therapy (LITT)
Customize your policy alerts
Sign up for healthspring Policy SUR701.031 alerts
Get alerted when Policy SUR701.031 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of magnetic resonance-guided laser interstitial tumor therapy for medically refractory epilepsy, brain tumors, and brain radiation necrosis, and identifies other uses as experimental, investigational, or unproven.
A new medical policy establishes that MRI-guided LITT for epilepsy, brain tumors, or brain radiation necrosis may be medically necessary when Coverage criteria are met, while all other indications are experimental, investigational, and/or unproven.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.